Back to results
US 4,753,894 AGranted
Monoclonal anti-human breast cancer antibodies
AssigneeCetus Corporation
InventorsArthur E. Frankel, David B. Ring, Michael J. Bjorn
Life of this patent
Estimating the term…
Abstract
Murine monoclonal antibodies are prepared and characterized which bind selectively to human breast cancer cells, are IgGs or IgMs, and when conjugated to ricin A chain, exhibit a TCID 50% against at least one of MCF-7, CAMA-1, SKBR-3, or BT-20 cells of less than about 10 nM. Methods for diagnosing, monitoring, and treating human breast cancer with the antibodies or immunotoxins made therefrom are described.
Claims29
A murine monoclonal antibody that:
- (a) binds selectively to human breast cancer cells;
- (b) has a G or M isotype;
- (c) when conjugated to ricin A chain, exhibits a TCID 50% of less than about 10 nM against at least one of MCF-7, CAMA-1, SKBR-3, or BT-20 cells;
- and
- (d) binds a human breast cancer antigen that is also bound by a reference antibody selected from the group consisting of 260F9, 113F1, 266B2, 454C11, 33F8, 317G5, 520C9, and 260F-9-1C9, as determined by immunoprecipitation or sandwich immunoassay.
2 more elements
Dependencies are inferred from the claim text.